Celgene Can't Shake Shareholder Suit Over Drug Trial
Celgene and several of its executives must face trimmed down securities fraud claims brought against them by investors who say the biotech company hyped up the value of a trial drug...To view the full article, register now.
Already a subscriber? Click here to view full article